Digital Trials Digest, our quarterly newsletter
Expectations for the time it takes to complete a vaccine clinical trial have been radically raised by the mRNA vaccines’ successes.
Decentralized trials (DCTs) expand older adults’ access to trials, allowing them to participate at higher rates.
Digital transformation is reshaping nearly every industry, and clinical trials are no exception. As technology plays a bigger role in healthcare, patients are demanding more access to medical research. It’s not just patients who are asking for more: Medical professionals, researchers, and pharmaceutical companies all want to improve quality, efficiency, and access to clinical trials.
The use of real world data in clinical trials is a hot topic. Doctors, biotech and pharmaceutical companies alike point to the tremendous potential to leverage this data to improve health outcomes.
Virtual clinical trials aren’t just a buzzword—these research models are here to stay. In fact, the global market for virtual clinical trials is expected to reach $12.9 billion by 2030, according to Grand View Research.
We know that a patient-centric approach to clinical trials generally leads to higher compliance and retention rates. DCTs are more convenient for participants.
In the first of our two-part series exploring minority participation in clinical trial research, we examine the numerous challenges to securing diversity in clinical trials and the consequences of primarily white patient populations.
ObvioHealth tackles misconceptions about decentralized clinical trials, they’re less safe, they’re always fully virtual, the data isn’t trustworthy, and so on.
BYOD ePRO models deliver a range of benefits to clinical trial stakeholders, including increased engagement, reduced site team burden, and more.
Digital therapeutics are playing an increasing role in mental health care. Ensuring that these DTx products meet quality thresholds is key to effective care.